Tess Hollis: Felix — good week, bad week, weird week?
Felix Ortiz: Weird week, honestly. I went down a rabbit hole on something and couldn't find the floor. You ever read an investigation and feel like the most alarming part is just sitting there not being discussed?
Tess Hollis: That's very specific for a Tuesday — what was it?
Felix Ortiz: Peptides. USA Today dropped this investigation October 18th, 2026, and the thing that just — it stayed with me — is this image of a regular person. Forty-two years old, climber, chronic shoulder tendinitis, sitting in a longevity clinic. Doctor slides a protocol across the desk. BPC-157. Describes it as, basically, a signal molecule your body already produces. Like a text message your cells send each other. And the analogy the doctor reaches for is Ozempic — semaglutide, GLP-1 drugs, the ones that are actually FDA-approved, the ones everyone's heard of. So it sounds legitimate.
Tess Hollis: Huh — because Ozempic actually went through trials.
Felix Ortiz: Right, that's the whole — yeah, that's the gap. GLP-1 receptor agonists are real peptide-based drugs, rigorous trials, FDA approval, the works. BPC-157 is also a peptide. So the category sounds the same. But the regulatory and safety path behind it is completely different, and the patient has no way to see that from inside the exam room.
Tess Hollis: So the credibility of Ozempic is laundering the credibility of everything else that gets called a peptide.
Felix Ortiz: That is — yeah, that's actually the cleanest version of what I was trying to say. And the USA Today investigation is what made that visible. Four red flags, one substantiated claim. The question today is what that climber doesn't know when she takes that vial home.
Tess Hollis: But the vial doesn't say — and this is where I keep getting stuck — the FDA is not actually speaking with one voice on any of this. An advisory panel narrowly voted to ease compounding restrictions on BPC-157, TB-500, four others. Narrow vote. Meanwhile, the agency's own staff scientists — separately, same compounds — concluded the available evidence doesn't demonstrate meaningful efficacy or adequate safety. Those are their words.
Felix Ortiz: Wait, the staff scientists said that and the panel still voted to loosen it?
Tess Hollis: Yes. Same agency, opposite conclusions, and it's basically gone unnoticed.
Felix Ortiz: Okay, so — I mean, that's the thing I couldn't square either. Because if you read the staff scientists' review, they're not hedging. And then the panel is just... going a different direction. How does that happen inside one institution?
Tess Hollis: That's the question, right? And it gets worse when you look at the specific compounds. For KPV — zero human safety studies. Not small. Zero. It's being compounded and sold right now.
Felix Ortiz: Zero? Like — not a single human trial for KPV, ever?
Tess Hollis: TB-500, MOTS-c, Epitalon — same. Zero. And for BPC-157, Semax, emideltide, there are some human studies, but the longest treatment period is around fifteen days. Practitioners are running month-long protocols. That gap is where the actual risk lives.
Felix Ortiz: So the panel voted to ease restrictions on compounds where the longest human data is — what, two weeks? And then our climber is doing four months of injections based on that.
Tess Hollis: Which raises the obvious question — what were they hearing in that room that the scientists weren't?
Felix Ortiz: And that's — okay, that question, 'what were they hearing,' that's where RFK Jr. becomes relevant, because it wasn't a vacuum. MAHA has been publicly pushing expanded access to these compounds all through 2026, and the advisory panel vote lands right in the middle of that. Like, the political pressure and the regulatory outcome are not coincidentally timed.
Tess Hollis: So the argument is — political movement, regulatory outcome, same window?
Felix Ortiz: Yeah, and the mechanism is actually the 503A/503B compounding framework — FDA adopted this three-category system for compounded peptides, Category 1, 2, 3, and the whole architecture of what's legal to compound is being reshaped around it. That's not abstract. That's the legal machinery that decides whether your longevity clinic can hand you a vial.
Tess Hollis: Right — but the legitimacy argument only works if people believe the compounds are safe. So what's providing that cover?
Felix Ortiz: Gary Brecka and Brigham Buhler. USA Today cites their recorded conversation specifically — Buhler, who co-wrote The Peptide Revolution and owns a compounding pharmacy, on record arguing peptides are safe because they're, quote, 'natural' or 'made by the human body.' And Brecka's amplifying it. That's the load-bearing myth. If you accept that frame, none of the missing trial data matters.
Tess Hollis: Matthew Zuckerman at the University of Colorado, the American Medical Association, Johns Hopkins researchers — all of them have explicitly flagged that logic as the problem. Your body makes cortisol. Dosage and source still matter.
Felix Ortiz: Yeah, and — wait, actually the part that makes this more broken is the gray market running underneath all of it. 'Research use only' vials, sold online, explicitly labeled not for human use. People are injecting them anyway. RFK's regulatory push doesn't touch that supply chain at all. It just makes the compounding pharmacy version more visible while the RUO stuff keeps moving.
Tess Hollis: So legitimization without enforcement is basically just branding.
Felix Ortiz: And the Brecka-Buhler naturalness argument is what makes people comfortable enough to order the RUO version in the first place — which is where the Ozempic comparison does something really specific and honestly kind of insidious, and that's the part we should get into next.
Tess Hollis: And that's the thing that actually sharpens the whole picture — because Ozempic isn't just a peptide, it's proof the model works. Semaglutide completed rigorous clinical trials. USA Today names GLP-1 receptor agonists as the one substantiated area of peptide efficacy. The one. So influencers aren't wrong that there's a successful FDA-approved peptide drug out there. They're just pointing at it and saying 'see, peptides work' — and then gesturing at BPC-157 like it's in the same sentence.
Felix Ortiz: Which is — yeah, that's the credibility bridge, and it's almost perfectly constructed. Because Ozempic is a real thing people know. It's on television. So when someone says 'peptide-based drug,' you have an anchor.
Tess Hollis: But the patient holding a vial of compounded BPC-157 has no way to verify it even contains BPC-157.
Felix Ortiz: Right, and — actually, no, wait — that's the part I keep wanting to move past and shouldn't. Because the FDA in November 2025 issued warnings specifically to sellers of semaglutide salts and research-use peptides. That was the precursor. That warning was already telling us the supply chain couldn't verify what was in the vial. And then the influencer cycle just... kept going.
Tess Hollis: So the warning existed before the 2026 investigation and it didn't change behavior.
Felix Ortiz: Apparently not. And here's the scenario that sticks with me — not our climber, a different one. Imagine someone who Googled Ozempic, knows it works, reads one Brecka video caption that says 'BPC-157 is made by your own body,' and orders a research-use-only vial online. No clinic, no doctor. That vial is labeled not for human use. They inject it. Who do they call if something goes wrong?
Tess Hollis: Nobody, legally. That's the liability gap — and we should be honest that we don't know yet how often harm is actually occurring. The sourcing is still thin on that.
Felix Ortiz: Which is — yeah, the uncertainty is the point, right? We can't quantify it. But that uncertainty exists because there's no tracking mechanism. No one's counting.
Tess Hollis: And the MAHA push for regulatory legitimization doesn't answer that question. It just makes the compounding pharmacy version look more official while the research-use-only market runs the same way it always did. That's not a science question anymore — what's the version of that you'd say to someone who thinks the regulatory win is the solution?
Felix Ortiz: The regulatory win is — yeah, it's a category error, right? Because the problem was never that the compounding pharmacy version was hard to get. Our climber from the top of this, she walked into a clinic, she walked out with a vial. That was already solved. The advisory panel vote just... makes the same transaction feel more official. The label changes. The uncertainty doesn't.
Tess Hollis: And the USA Today investigation named exactly one substantiated claim across all of this. One. The peptide drug that works — the GLP-1 agonist, semaglutide — is the one that went through trials. That's not a coincidence. That's the answer.
Felix Ortiz: She's going home tonight thinking she's getting something like Ozempic — a molecule her body already makes, a little more of it, basically safe. She doesn't know the FDA's own staff scientists said the evidence isn't there. She doesn't know the advisory panel that narrowly voted to ease restrictions was contradicting those same scientists. And her vial, not that long ago, said 'not for human use' on it. I don't know what to do with that except just... let it sit.
